Invitation - Presentation of Orexo's third quarter results 2014
Uppsala, Sweden – October 15, 2014 - On October 22 at 08:00 am, Orexo AB (publ) will publish its report for the third quarter 2014.
Financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the third quarter results, at 1:30 pm CET (07:30 am EDT). The event will be hosted by Orexo's CEO and President Nikolaj Sørensen and CFO Henrik Juuel. The general and financial presentation will this time be followed by an update on the ISTART study results presented by Chief Medical Officer Michael Sumner. The presentation will be held in English.
The presentation can be followed live, or afterwards on www.orexo.com, where the slides used in the presentation will be made available.
To participate in the telephone conference, please call:
SE: +46 8 519 993 59
UK: +44 203 194 0553
US: +1 855 269 2607
To view the presentation, please visit financialhearings.nu/141022/orexo.
For further information, please contact:
Beata Augenblick, Investor Relations
Tel: +46 (0)18-780 88 00, E-mail: [email protected]
Orexo is a specialty pharma company with commercial operations in the United States and R&D in Sweden developing improved treatments using proprietary drug delivery. The company is commercializing its proprietary product, ZUBSOLV® sublingual tablets, for maintenance treatment of opioid dependence, in the United States. The ZUBSOLV sublingual tablet is a novel formulation of buprenorphine and naloxone using Orexo’s extensive knowledge in sublingual technologies. Orexo has a portfolio of two approved and revenue generating products currently marketed under license in the US, EU and Japan. Orexo AB, with its headquarters in Sweden, is listed on Nasdaq Stockholm Exchange and its American Depositary Receipts (ADRs) trade on the OTCQX marketplace in the U.S. under the symbol, “ORXOY”. The largest shareholders are Novo A/S and HealthCap.
For information about Orexo, please visit www.orexo.com
Orexo AB (publ) discloses the information provided herein pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 5:15 pm CET on October 15, 2014.